Abstract

Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant vascular disorder characterized by spontaneous epistaxis, telangiectasia, and visceral vascular malformations. Hepatic vascular malformations are common, though a minority are symptomatic. Symptoms are dependent on the severity and exact type of shunting caused by the hepatic malformation: Arteriosystemic shunting leads to manifestations of high output cardiac failure, and arterioportal shunting leads to portal hypertension. Radiologic imaging, including ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI), is an important tool for assessing liver involvement. Doppler ultrasonography is the first-line screening modality for HHT-related liver disease, and it has a standardized scale. Imaging can determine whether shunting is principally to the hepatic vein or the portal vein, which can be a key determinant of patients’ symptoms. Liver-related complications can be detected, including manifestations of portal hypertension, focal liver masses as well as ischemic cholangiopathy. Ultrasound and MRI also have the ability to quantify blood flow through the liver, which in the future may be used to determine prognosis and direct antiangiogenic therapy.

Highlights

  • Hereditary hemorrhagic telangiectasia (HHT), called Osler–Weber–Rendu, is an autosomal dominant disorder characterized by arteriovenous malformations (AVMs) throughout the body [1]

  • The proteins encoded by ENG and ACVRL1, endoglin and activin receptor-like kinase 1 (ALK1) are endothelial receptors involved in the transforming growth factor beta (TGF-β) signaling pathway [3,4]

  • The TGF-β signaling pathway, which is involved in angiogenesis and in maintaining vascular integrity, is defective or impaired in patients with HHT [5]

Read more

Summary

Introduction

Hereditary hemorrhagic telangiectasia (HHT), called Osler–Weber–Rendu, is an autosomal dominant disorder characterized by arteriovenous malformations (AVMs) throughout the body [1]. The physiologic manifestations of HHT in the liver reflect the unique nature of its blood supply. Liver telangiectases are early manifestations of hepatic involvement in HHT [14].

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.